streptavidin fusion protein (NeoRx/NIH)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namestreptavidin fusion protein (NeoRx/NIH)
Drug Alias Name213Bi-labeled radioimmunotherapy (NIH)bismuth-213-DOTA-biotinanti-Tac-streptavidin fusion proteins (NeoRx/NIH)213Bi-DOTA-biotin
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-2 receptor antagonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsLymphoma, T-CellLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthPoniard Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, T-CellLeukemia

Other Information

ATC CodeN/A
Related LinksN/A